Candel Therapeutics

During #MensHealthWeek, we reflect on our commitment to developing treatments for prostate, lung, & pancreatic cancer. Our experimental medicines show promising results with potential to transform treatment paradigms & offer hope for patients with difficult-to-treat solid tumors.

Exciting milestone! The EMA granted Orphan Drug Designation for CAN-2409 in pancreatic cancer. This adds to our FDA Orphan Drug & Fast Track Designations, reinforcing the unmet need in this disease. ir.candeltx.com/news-releases/… $CADL

#ICYMI @BradLoncar at @BiotechTV and our CEO, @paulpetertak, discussed CAN-2409's phase 3 prostate cancer data and our strategy across multiple solid tumors at #ASCO25! Watch: biotechtv.com/post/candel-th…

Throwback to Kyle's inspiring 2023 story on WCVB about how a clinical trial of CAN-3110 gave her ‘the gift of time’, living with glioblastoma. Her journey inspires us to advance CAN-3110 for recurrent high-grade glioma. Watch: wcvb.com/article/boston… #BrainCancer #GBMDay $CADL

Today is #GlioblastomaAwarenessDay. We honor those lost to GBM & stand with patients, families & caregivers affected. At Candel, we're advancing CAN-3110, a first-in-class, next generation viral immunotherapy for recurrent high-grade glioma. braintumor.org/events/gliobla… #GBMDay

Thanks @Labiotech_eu for featuring us in a lung cancer companies article! CAN-2409 achieved 24.5 months median overall survival (mOS) in #NSCLC with an inadequate response to ICIs, markedly better than mOS in published control patients treated with chemo. labiotech.eu/best-biotech/l…

We're pleased to be added to multiple Russell Value indexes in 2025 reconstitution, including Russell 2500 Value, Small Cap Value, 2000 Value, Microcap Value & 3000E Value indexes. We also maintained our membership in the Russell 3000 Index. ir.candeltx.com/news-releases/… $CADL

#ICYMI: @FierceBiotech highlighted our successful phase 3 prostate cancer trial. The study demonstrated a statistically significant 30% reduction in disease recurrence risk fiercebiotech.com/biotech/candel… #ProstateCancer $CADL

Wishing everyone a fun and safe 4th of July holiday. Happy Independence Day! #IndependenceDay #4thofJuly

Thank you @HemOncToday for featuring our phase 2 trial of CAN-2409, showing 24.5 month median OS in advanced #NSCLC patients with an inadequate response to immune checkpoint inhibitors. Particularly encouraging results in nonsquamous histology patients. healio.com/news/hematolog…

We're pleased to announce a $15M registered direct offering to advance pre-commercialization activities for CAN-2409 in prostate cancer. Supported by existing institutional investors and company leadership as we work to transform cancer treatment. ir.candeltx.com/news-releases/…

We're pleased to announce Charles Schoch as our new CFO! His understanding of our business will be instrumental as we advance our clinical pipeline, prepare for BLA submission for CAN-2409 in localized prostate cancer, and execute on corporate goals. ir.candeltx.com/news-releases/…

Pharma Features spoke to our CTDO, Dr. Tyagarajan! She discusses how her cross-platform expertise supports the advancement of Candel's leading adenoviral platform, HSV platform, and enLIGHTEN™ Discovery Platform. Read here: pharmafeatures.com/enhancing-anal…

We're proud to see CAN-2409's promising results in @Labiotech_eu on the future of #NSCLC treatment! Our phase 2a results showed 24.5 months median overall survival in advanced NSCLC patients who had an inadequate response to immune checkpoint inhibitors. labiotech.eu/in-depth/futur…

Read how Candel is advancing cancer immunotherapies through our viral delivery platform in this @DDWJournal interview with our CEO @paulpetertak. Our approach teaches immune cells to recognize and attack cancer cells directly in tumors. ddw-online.com/gene-delivery-… $CADL

Last week we announced the appointment of Maha Radhakrishnan, M.D., to our Board of Directors! Maha brings 20+ years of biotech leadership experience in product development & commercialization. ir.candeltx.com/news-releases/… #Leadership #CancerTherapeutics $CADL

Join our CSO, Francesca Barone, M.D., Ph.D., as she participates in a webinar with Cell & Gene. Candel brings expertise across two clinical-stage viral platforms: adenovirus (CAN-2409) & HSV (CAN-3110), plus our enLIGHTEN™ Discovery Platform. Tune in: event.on24.com/wcc/r/4954402/…

#ICYMI: @FierceBiotech covered how our CAN-2409 lung cancer survival data is lighting the path toward a pivotal trial in nonsquamous NSCLC patients, who showed remarkably strong disease control with median OS of 25.4 months. fiercebiotech.com/biotech/candel…

Thank you to everyone who joined us for our event at the historic Glessner House during ASCO 2025! It was a wonderful opportunity to connect with colleagues, share our excitement about the positive CAN-2409 phase 3 prostate cancer data, and celebrate this milestone together.

Our phase 3 trial data for CAN-2409 in prostate cancer will be presented at #ASCO2025 by Dr. DeWeese, Dean of Medical Faculty & CEO at Johns Hopkins. The findings represent the first potential new treatment for localized prostate cancer in over 20 years. ir.candeltx.com/news-releases/…